FCMT
CPRX

Founders Capital Management (Texas)’s Catalyst Pharmaceutical CPRX Stock Holding History

Founders Capital Management (Texas)’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.9K Hold
600
– – 0.01% 287
2025
Q4 		$14K Hold
600
– – 0.01% 281
2025
Q3 		$11.8K Buy
+600
New +$12.3K 0.01% 280

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Founders Capital Management (Texas)'s CPRX Position: Q1 2026 in Review

Founders Capital Management (Texas) held its Catalyst Pharmaceutical (CPRX) position steady in Q1 2026 at 600 shares worth $14.9K. The position accounts for 0.01% of the portfolio, ranked #287.

Founders Capital Management (Texas) first reported a position in CPRX in Q3 2025 and has held it in 3 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Founders Capital Management (Texas) held 600 shares of Catalyst Pharmaceutical worth $14.9K as of Q1 2026.
  • Founders Capital Management (Texas) left its Catalyst Pharmaceutical share count unchanged in Q1 2026.
  • Catalyst Pharmaceutical made up 0.01% of Founders Capital Management (Texas)'s portfolio in Q1 2026, its #287 holding.
  • Founders Capital Management (Texas) first reported a position in Catalyst Pharmaceutical in Q3 2025 and has held it in 3 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Founders Capital Management (Texas)'s 13F filing for Q1 2026, filed 21 Apr 2026.